Comparative Pharmacology
Head-to-head clinical analysis: FORTESTA versus TESTOSTERONE PROPIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORTESTA versus TESTOSTERONE PROPIONATE.
FORTESTA vs TESTOSTERONE PROPIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone replacement therapy; testosterone binds to and activates androgen receptors, influencing gene transcription and protein synthesis, leading to the development of male secondary sex characteristics and maintenance of libido, muscle mass, and bone density.
Testosterone propionate is a short-acting androgen receptor agonist. It binds to androgen receptors, leading to activation of androgen-responsive genes and promotion of male secondary sexual characteristics, anabolic effects, and erythropoiesis.
Apply one 30 mg metered-dose transdermal system to abdomen or upper arm once daily at the same time each day.
50-400 mg intramuscularly every 2-4 weeks. For androgen replacement, 50-100 mg IM every 2 weeks.
None Documented
None Documented
Clinical Note
moderateTestosterone propionate + Tranylcypromine
"The risk or severity of adverse effects can be increased when Testosterone propionate is combined with Tranylcypromine."
Clinical Note
moderateTestosterone propionate + Procarbazine
"The risk or severity of adverse effects can be increased when Testosterone propionate is combined with Procarbazine."
Clinical Note
moderateTestosterone propionate + Pirlindole
"The risk or severity of adverse effects can be increased when Testosterone propionate is combined with Pirlindole."
Clinical Note
moderateTerminal elimination half-life is 3–4 hours; not clinically significant for once-daily transdermal administration due to sustained absorption.
Terminal half-life: 0.8–1.2 hours (rapid elimination due to short ester chain; requires frequent dosing).
Primarily renal (90% as glucuronide and sulfate conjugates, 10% unchanged); approximately 1% fecal.
Renal: 90% (as glucuronide and sulfate conjugates); Fecal/Biliary: 10%.
Category C
Category D/X
Androgen
Androgen
Testosterone propionate + Moclobemide
"The risk or severity of adverse effects can be increased when Testosterone propionate is combined with Moclobemide."